Simple blood test could catch myeloma years earlier in High-Risk groups
NCT ID NCT06644625
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This study aims to detect multiple myeloma at its earliest stage, called MGUS, using a simple blood test. It will screen 1,665 Black adults and close relatives of people with plasma cell disorders. The goal is to reduce delayed diagnosis and improve outcomes by catching the disease before it progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Levine Cancer
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Blood draw for MGUS screening
What this could lead to
If successful, this screening approach could help catch multiple myeloma at an earlier, more treatable stage, potentially improving long-term survival.
What could go wrong
This is an early pilot study focused on feasibility, not yet proven to reduce harm. Many people with MGUS never develop myeloma, so screening may cause unnecessary worry or testing.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.